GGHC
MYOV

Gilder Gagnon Howe & Co’s Myovant Sciences Ltd. MYOV Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-184,128
Closed -$2.59M – 359
2020
Q3 		$2.59M Buy
184,128
+531
+0.3% +$9.88K 0.02% 227
2020
Q2 		$3.79M Buy
+183,597
New +$2.5M 0.03% 188

Other funds holding MYOV

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return

Gilder Gagnon Howe & Co's MYOV Position: Q4 2020 in Review

Gilder Gagnon Howe & Co sold out of Myovant Sciences Ltd. (MYOV) in Q4 2020, closing a stake of 184,128 shares — an estimated $2.59M sold.

Gilder Gagnon Howe & Co first reported a position in MYOV in Q2 2020 and held it in 2 quarters. The position peaked at $3.79M in Q2 2020. 105 funds tracked by Wall St. Rank hold MYOV as of Q4 2020.

  • Gilder Gagnon Howe & Co reported no remaining Myovant Sciences Ltd. position as of Q4 2020 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 184,128 Myovant Sciences Ltd. shares in Q4 2020, an estimated $2.59M.
  • Gilder Gagnon Howe & Co first reported a position in Myovant Sciences Ltd. in Q2 2020 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's Myovant Sciences Ltd. position peaked at $3.79M in Q2 2020.
  • 105 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q4 2020.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2020, filed 16 Feb 2021.